期刊文献+

黑皮质素受体在破骨细胞形成中的作用

Effect of melanocortin receptors on osteoclastogenesis
原文传递
导出
摘要 目的观察由Raw264.7细胞诱导破骨细胞形成过程中黑皮质素受体(MCR)的作用。方法用α-促黑素(α-MSH)及其类似物SHU9119、PT141、THIQ分别处理体外培养的Raw 264.7细胞,并依此分为对照组、α-MSH组、SHU9119组、PT141组、THIQ组和α-MSH加SHU9119组。培养6天后,经抗酒石酸酸性磷酸酶染色后,观察并计数各组破骨细胞形成数目。RT-PCR法测定Raw 264.7细胞表达的MCR种类。结果在Raw 264.7细胞诱导破骨细胞过程中,α-MSH呈剂量依赖性的增加了破骨细胞形成。SHU9119组、PT141组及α-MSH加SHU9119组均显著增加了破骨细胞形成数目(P<0.05);但THIQ处理组对破骨细胞形成无统计学意义(P>0.05)。Raw 264.7细胞表达5种MCR。结论 MCR激动剂能显著增加破骨细胞形成数目,可能主要通过结合MCR1和/或MCR5促进破骨细胞形成。 Objective To investigate the effect of melanocortin receptor(MCR) in the process of osteoclastogenesis which was induced by Raw 264.7 cells.Methods Raw264.7 cells were treated with α-melanocyte stimulating hormone(α-MSH) and its analogues respectively,which were divided into control group,α-MSH group,SHU9119 group,PT141 group,THIQ group and α-MSH+SHU9119 group.The number of osteoclasts was observed by Tartrate-resistant acid phosphatase(TRAP) staining after 6 days.RT-PCR was used to determine the type of MCR in Raw264.7 cells.Results α-MSH dose-dependently increased osteoclastogenesis.The number of osteoclasts were significantly increased after treated with SHU9119 group,α-MSH+SHU9119 group and PT141 group(P〈0.05),but the THIQ group had no significant effect on osteoclastogenesis(P〉0.05).RT-PCR showed that all of the MCRs were expressed in Raw264.7 cells.Conclusion MCR agonists could markedly increase the number of oateoclasts,and this process might through M1CR and/or MC5R to complete.
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2012年第7期531-533,共3页 The Chinese Journal of Clinical Pharmacology
基金 国家自然科学基金资助项目(30660070) 东省中青年科学家科研奖励基金资助项目(BS2010YY002)
关键词 黑皮质素受体 促黑素 破骨细胞形成 melanocortin receptor; α-melanocyte stimulating hormone; osteoclastogenesis
  • 相关文献

参考文献9

  • 1Cornish J, CaIon KE, Mountjoy KG, et al. Alpha - melanocyte - stimulating hormone is a novel regulator of bone [ J ]. Am J Physiol Endocrinol Metab, 2003 ; 284 : l 181 - 1190.
  • 2Robling AG, Castillo AB, Turner CH. Biomechanical and molecular regulation of bone remodeling [ J]. Ann Rev Biomed Eng, 2006; 8: 455 - 498.
  • 3Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and ac- tivation [ J]. Nature, 2003 ; 423 : 337 - 342.
  • 4Jules J, Ashley JW, Feng X. Selective targeting of RANK signaling pathways as new therapeutic strategies for osteoporosis [ J ]. Expert Opin Ther Targets, 2010; 14:923 -934.
  • 5Gantz I, Fong TM. The melanocortin system [ J]. Am J Physiol En- docrinol Metab , 2003; 284:468-474.
  • 6Nahon JL. The melanocortins and melanin - concentrating hormone in the central regulation of feeding behavior and energy homeostasis [J]. C R Biol, 2006; 329:623 -638.
  • 7Brzoska T, Luger TA, Maaser C, et al. Alpha - melanocyte - stimu- lating hormone and related tripeptides: biochemistry, antiinflammato- ry and protective effects in vitro and in vivo, and future perspectives for the treatment of immune - mediated inflammatory diseases [ J ]. Endocr Rev, 2008 ; 29:581 -602.
  • 8Zhong Q, Sridhar S, Ruan L, et al. Multiple melanocortin receptors are expressed in bone ceils [J]. Bone, 2005 ; 36:820 - 831.
  • 9Dumont LM, Wu CS, Tatnell MA, et al. Evidence for direct actions of melanocortin peptides on bone metabolism [ J ]. Peptides, 2005; 26 : 1929 - 1935.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部